ARCUTIS BIOTHERAPEUTICS INC (ARQT)
Health Care · biopharmaceuticals · NASDAQ
Arcutis Biotherapeutics is a commercial-stage dermatology company delivering innovative, targeted treatments for immune-mediated skin conditions.
What ARCUTIS BIOTHERAPEUTICS INC does
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological conditions. The company's portfolio addresses significant unmet needs in inflammatory skin diseases. Its lead commercial activities center on therapies for conditions such as plaque psoriasis and seborrheic dermatitis.
Themes: dermatology, plaque psoriasis treatments, seborrheic dermatitis treatments, inflammatory skin disease therapeutics
Fundamentals
- Price$24.49 as of 2026-10-08 close
- Market cap$3.1B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+15.3% 2025-10-08 close $21.24 → 2026-10-08 close $24.49
- P/E114.17 as of 2026-10-08
- Net margin-4.3% FY2025, SEC XBRL
- ROE-8.5% FY2025, SEC XBRL
- Debt / equity0.49 as of 2026-09-03
- Revenue growth (YoY)+76.1% as of 2026-09-03
- Revenue CAGR (3y)+367.3% SEC XBRL
- Beta1.19 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How ARQT compares in its sector
- price-to-earnings ratiotop 10% 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ARCUTIS BIOTHERAPEUTICS INC looks technically
ARCUTIS BIOTHERAPEUTICS INC (ARQT) is trading 2.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 47 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day high about 13 trading days ago. It is 22.9% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 2.9% below its 200-day average, the long-term trend line — a long-term downtrend | -2.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $25.42 | $25.42 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $25.21 | $25.21 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 47 trading days ago — a "golden cross", a bullish long-term signal | 47 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 18.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 44.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($23.37 to $28.29) — its "stochastic" reading is 23 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 22.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $31.77 | $31.77 |
|---|---|---|
| From the 52-week high | it is 22.9% below its 52-week high (its highest price of the past year) | -22.9% |
| Above the 52-week low | it is 26.9% above its 52-week low (its lowest price of the past year) | +26.9% |
| Below the 52-week high | it is 22.9% below its highest point of the past year | 22.9% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day low about 21 trading days ago | 21 sessions |
| All-time high | its highest closing price on record is $40.88 (set on 2020-03-20) | $40.88 |
| Given back of the 52-week move | over the past year its closes ranged ($19.50 to $31.20), and it has recovered roughly a third of its fall from last year’s high — 43% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $26.73 to $27.11. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 42.6% |
| From the all-time high | it is 40.1% below its all-time high | -40.1% |
| Nearest price level | it is sitting right on a support level at $24.38 — a price it turned at twice since 2026-02-02, most recently on 2026-05-06. Since 2024-10-08 it has 13 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $1.76 (set on 2023-12-01) | $1.76 |
| Above the all-time low | it is 1291.5% above its all-time low | +1,291% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 61st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.19 between its high and its low — about 4.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.19 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $23.16 and $28.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $23.16 – $25.58 – $28.01 |
| Typical daily range (% of price) | its price moves about 4.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.9% |
| Stretch from the 200-day average | it is trading 0.6 daily ranges below its 200-day average price (2.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.86× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.1% |
|---|---|---|
| Gap filled | a 3.9% gap up opened on 2026-09-08 has been "filled" 21 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 21 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +2.38% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 0.6 percentage points (the stock gained 0.4% while the market gained 1.0%) | -0.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 17.9 percentage points (the stock lost 14.1% while the market gained 3.8%) | -17.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 13.9 percentage points (the stock gained 3.5% while the market gained 17.5%) | -13.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 0.3 percentage points (the stock gained 15.3% while the market gained 15.0%) | +0.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.2% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.0% of the share price. | -4.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $25.02 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -2.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $25.42 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | -3.6% |
Price levels it has turned at before
ARQT last closed at $24.49 on 2026-10-08. Since 2024-10-08 it has turned at 13 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $24.38 | Support | 0.5% below the last close | turned there twice · 2026-02-02 to 2026-05-06 |
| $25.07 | Resistance | 2.4% above the last close | turned there four times · 2026-01-20 to 2026-09-08 |
| $25.50 | Resistance | 4.1% above the last close | turned there twice · 2026-03-10 to 2026-04-14 |
| $23.05 | Support | 5.9% below the last close | turned there three times · 2026-03-04 to 2026-09-15 |
| $22.07 | Support | 9.9% below the last close | turned there four times · 2025-10-16 to 2026-05-27 |
| $27.12 | Resistance | 10.7% above the last close | turned there three times · 2025-10-30 to 2026-08-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · lagging the market · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$37.00 range $34.00 – $40.00; median $38.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ARQT
- Consensus EPS estimate$0.172 next reporting period, as of 2026-10-05
- Estimate change, 30 days+$0.01367 (+8.6%) from $0.1583, on 2026-09-01, 34-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["dependence on continued successful commercialization of current products","significant capital requirements and history of accumulated deficits","intense competition in the dermatology and immunology markets"]
What changed in the latest 10-Q
AI-assisted comparison of ARQT's 10-Q filed 2026-08-05 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states FDA approval for expanded plaque psoriasis indication down to 2 years of age was received in June 2026 (older described a pending sNDA with PDUFA date of June 29, 2026).
- Newer filing adds that the company 'has built a dedicated commercial team' to execute promotion of ZORYVE to primary care practitioners and pediatricians following the Kowa agreement termination.
- Newer filing states the sNDA for ZORYVE cream 0.05% in infants has been assigned a PDUFA target action date of February 23, 2027 (older did not include a PDUFA date).
- Removed:
- Older filing includes a description that the sNDA to expand ZORYVE cream 0.3% for plaque psoriasis in children down to age 2 was accepted for filing in November 2025, with PDUFA target action date June 29, 2026.
- Older filing states the sNDA for ZORYVE cream 0.05% infant indication was submitted to the FDA in April 2026.
- Reworded:
- Older filing describes FDA approval for ZORYVE foam for plaque psoriasis of scalp and body as received in May 2025, followed by U.S. commercial launch in June 2025, and separately describes Health Canada approval in October 2025 with launch in November 2025. Newer filing describes FDA approval followed by U.S. launch in June 2025 and Canada launch in November 2025 without stating approval months.
- Older filing states Health Canada approval for ZORYVE cream 0.15% was received in March 2025; newer filing omits the Health Canada approval month, saying only it was commercially launched in Canada in April 2025.
- Older filing says 'our Supplement to a New Drug Submission (SNDS)' for ZORYVE cream 0.3%; newer says 'we' received acceptance, with minor wording variations.
- Older filing says 'we announced positive topline data'; newer says 'we announced positive top-line data' (hyphenation change).
- Notes:
- The provided texts appear to be truncated at the end of the Overview section in both filings; only the visible portions were compared.
- In the newer filing, the sentence about the dedicated commercial team reads 'we has built' in the source text, which may be a typographical error in the filing itself and was interpreted as 'we have built.'
Risk Factors
- Added:
- Newer filing (2026-08-05): Added disclosure that Todd Franklin Watanabe terminated a Rule 10b5-1 trading plan on June 4, 2026, which had been adopted March 13, 2026, covering potential sale of up to 325,000 shares between June 12, 2026 and June 11, 2027, with no shares sold prior to termination.
- Newer filing (2026-08-05): Added disclosure that Todd Franklin Watanabe entered into a new Rule 10b5-1 trading plan on June 5, 2026, covering potential exercise and sale of up to 325,000 options between August 27, 2026 and August 31, 2027.
- Newer filing (2026-08-05): Added disclosure that Masaru Matsuda, Chief Legal Officer, entered into a Rule 10b5-1 trading plan on June 9, 2026, covering potential exercise and sale of up to 40,000 options and potential sale of 45,792 shares of common stock between September 8, 2026 and September 1, 2027.
- Removed:
- Older filing (2026-05-06): Removed disclosure that Howard G. Welgus, M.D., a Board member, entered into a Rule 10b5-1 trading plan on March 13, 2026, covering potential exercise and sale of up to 49,134 options and potential sale of 7,609 shares resulting from RSUs vesting between June 15, 2026 and June 15, 2027.
- Older filing (2026-05-06): Removed disclosure that Todd Franklin Watanabe entered into a Rule 10b5-1 trading plan on March 13, 2026 covering potential sale of up to 325,000 shares between June 12, 2026 and June 11, 2027.
- Reworded:
- Exhibit 10.1 incorporate-by-reference form number changed from '4.3' in the older filing to '99.1' in the newer filing for the Arcutis Biotherapeutics, Inc. Amended and Restated 2022 Employment Inducement Incentive Plan.
- Exhibit 10.2 added in newer filing, referencing an Amended and Restated Non-Employee Director Compensation Program incorporated by reference from Form 8-K dated June 9, 2026, exhibit 10.1; no such exhibit appears in the older filing.
- Form date for exhibit 10.1 (Form S-8) is listed as 4/21/26 in both filings, with no change noted.
- Notes:
- The provided texts appear to be a combined section containing Item 1A Risk Factors plus subsequent items (Items 2-6) rather than Risk Factors alone.
- The 'Risk Factors' disclosure sentence itself ('no material changes to the risk factors disclosed in our Annual Report...') is identical in both filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 14 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 2 sells ($206225) — 2 selling insiders
- Last 90 days · read to 2026-10-040 buys · 14 sells ($2M) — 5 selling insiders
- Last 180 days · read to 2026-10-040 buys · 25 sells ($3M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-16. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ARQT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 3 matched disclosures for ARQT from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ARQT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 19,269,902
- Reported value $505,256,824
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ARQT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ARQT had 18,458,091 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ARQT had 14.7% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.54 days to cover at the same settlement.
- Reported short interest (shares) 18,458,091
- Short interest (% of shares outstanding) 14.7%
- Prior settlement (shares) 16,557,048
- Reported change 11.48%
- Days to cover (reported) 8.54
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Incyte (INCY)
- Bristol Myers Squibb (BMY)
- Galderma (GDER)
- AbbVie (ABBV)
- Amgen (AMGN)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ARQT vs…
ARCUTIS BIOTHERAPEUTICS INC is found in…
ARQT ranks in…
Frequently asked questions
What does ARCUTIS BIOTHERAPEUTICS INC (ARQT) do?
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological conditions. The company's portfolio addresses significant unmet needs in inflammatory skin diseases. Its lead commercial activities center on therapies for conditions such as plaque psoriasis and seborrheic dermatitis.
What sector is ARCUTIS BIOTHERAPEUTICS INC (ARQT) in?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) is classified in the Health Care sector. Its industry is biopharmaceuticals. It trades on NASDAQ.
Who are ARCUTIS BIOTHERAPEUTICS INC's (ARQT) competitors?
Notable peers of ARCUTIS BIOTHERAPEUTICS INC (ARQT) include Incyte, Bristol Myers Squibb, Galderma, AbbVie and Amgen. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in ARQT?
Yes — we hold 3 matched STOCK Act disclosures for ARQT from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ARCUTIS BIOTHERAPEUTICS INC (ARQT) overbought or oversold right now?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ARQT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.